PT-141 dosage, half-life, timing
A medicine’s amount, its time in blood and a person’s experience answer different questions. The label is precise about some of them.
Label figures for premenopausal women
The approved PT-141 dosage for women with HSDD is 1.75 mg subcutaneously. Subcutaneous means beneath the skin. That figure concerns premenopausal women with acquired, generalized low desire that causes distress, using the approved prefilled injection.
A laboratory powder and the approved injection have different safeguards. An individual treatment amount requires a clinician’s assessment.
What risks explain the limits in the prescription label
The US prescribing information specifies a PT-141 dosage of 1.75 mg administered subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month [6]. The approved product is a prefilled subcutaneous autoinjector, not a reconstituted powder [6]. These figures are the approved-label record for the HSDD indication in premenopausal women; they are reported here as the label specifies them, not as a protocol any reader should follow.
The per-24-hour limit is not arbitrary. It is partly informed by the transient blood-pressure increase the drug produces, which is also why the label contraindicates use in uncontrolled hypertension or known cardiovascular disease [6]. See tolerability and adverse events for that safety boundary in full.
Beyond these study figures, prescription requests for PT-141 (bremelanotide) go to Promise Peptides at mypromise.com. Clinicians there are prescribing it now. Its prescription-only care starts with a licensed U.S. clinician checking your health, and clinicians decline some requests. Patients are accepted from within the United States only; the care offered in one state or for one treatment may differ from another. Compounded PT-141 medicine has no FDA approval; the approved bremelanotide injection is a separate product.
PT-141 half-life
The prescribing information gives a terminal half-life of approximately 2.7 hours, with a range of 1.9–4.0 hours after subcutaneous administration. Half-life describes the time taken for the amount in blood to fall by half. It is a measurement of drug disposition.
I prefer that plain description to treating half-life as a countdown for desire. The label’s blood measurements answer a pharmacokinetic question; a person’s interest in sex requires a separate observation. About 21% serum-protein binding and breakdown through peptide-bond hydrolysis describe further aspects of how the body handles bremelanotide, rather than the strength of an individual experience.
Duration of reported desire
How long does PT-141 last? The answer depends on the effect being measured.
In the brain-imaging crossover study, women with HSDD reported increased sexual desire for up to 24 hours. The approximately 2.7-hour terminal half-life comes from blood-level measurements. They describe different things, so the figures can sit together without supplying a personal timetable.
When timing comes up, my first question concerns the effect being timed. Desire, a blood concentration and an unwanted symptom can follow different courses. Community accounts add descriptions of variable onset and duration, but those anecdotes cannot establish a schedule.